{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:28:28Z","timestamp":1789687708179,"version":"4.0.1"},"reference-count":0,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EJR"],"abstract":"<jats:p>Objective:\u00a0This study aims to examine the efficacy and safety of the antitumor necrosis factor (TNF) drugs in ankylosing spondylitis (AS) patients with chronic kidney disease.\n\nMethods:\u00a0In this study, 24 male patients with a glomerular filtration rate (GFR) of\u00a0&lt;60 mL min1\u00a01.73 m2\u00a0were included among 863 patients who were followed-up once in 3 months regularly from 2010 to 2018years. Twenty-four patients were chosen for the control group among 420 male patients whose renal functions were normal using random sampling. We examined C-reactive protein, erythro- cyte sedimentation rate, serum creatinine, and GFR values, and also the measurements of Bath Anky- losing Spondylitis Disease Activity Index (BASDAI) were recorded at the beginning of the treatment with anti-TNF agents and in the 3rd, 6th, 9th, 12th, and final visit months.\n\nResults:\u00a0Eleven (45.9%) of the patients included in the study were in the routine dialysis program. The initial anti-TNF treatments were etanercept (62.5%), infliximab (16.7%), adalimumab (16.7%), and goli- mumab (4.1%). Treatment was effective in 22 (91.7%) of the patients. When the values of the two groups\u2019 patients were compared at the beginning of the treatment, there was a substantial reduction regarding BASDAI (P\u00a0&lt;\u00a0.001). Pleural effusion, infective endocarditis, septic arthritis, and prosthesis infection were major side effects (n\u00a01\u20444\u00a04). The mortality rate of the 24 patients was 29.2% (n\u00a01\u20444\u00a07).\n\nConclusion:\u00a0This study demonstrated that anti-TNF drug treatment is effective and safe in patients with AS who have chronic kidney disease.\n\nCite this article as: Co\u015fkun BN, Ya\u011f\u0131z ,\u00c7orabay SG, Pehlivan Y, Dalk\u0131l\u0131\u00e7\u00a0E. Anti- TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe?\u00a0Eur J Rheumatol.2022;9(2):68-74.\n\n\u00a0\n\n\n<\/jats:p>","DOI":"10.5152\/eurjrheum.2022.21099","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T08:24:02Z","timestamp":1648023842000},"page":"68-74","source":"Crossref","is-referenced-by-count":8,"title":["Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe?"],"prefix":"10.5152","volume":"9","author":[{"given":"Belk\u0131s Nihan","family":"Co\u015fkun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Ya\u011f\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seniha","family":"G\u00fcnd\u00fcz \u00c7orabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ediz","family":"Dalk\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3111","published-online":{"date-parts":[[2022,3,23]]},"container-title":["European Journal of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/download\/515\/515","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T07:10:32Z","timestamp":1753773032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/view\/515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,4,26]]}},"URL":"https:\/\/doi.org\/10.5152\/eurjrheum.2022.21099","relation":{},"ISSN":["2148-4279"],"issn-type":[{"value":"2148-4279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]}}}